YU23901A - Upotreba sredstva za snižavanje holesterola u sprečavanju i odlaganju revaskularizacije pomoću katetera - Google Patents

Upotreba sredstva za snižavanje holesterola u sprečavanju i odlaganju revaskularizacije pomoću katetera

Info

Publication number
YU23901A
YU23901A YU23901A YU23901A YU23901A YU 23901 A YU23901 A YU 23901A YU 23901 A YU23901 A YU 23901A YU 23901 A YU23901 A YU 23901A YU 23901 A YU23901 A YU 23901A
Authority
YU
Yugoslavia
Prior art keywords
preventing
lowering agent
cholesterol lowering
based revascularization
catheter
Prior art date
Application number
YU23901A
Other languages
English (en)
Inventor
Donald Michael Black
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22289955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU23901(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of YU23901A publication Critical patent/YU23901A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

Naglo snižavanje holesterola kod pacijenata koji pate od bolesti koronarne arterije sprečava ili odlaže potrebu za revaskularizacijom pomoću katetera.[Aggressively lowering cholesterol in patients suffering from coronary artery disease prevents or delays the need for catheter-based revascularization.
YU23901A 1998-09-30 1999-07-08 Upotreba sredstva za snižavanje holesterola u sprečavanju i odlaganju revaskularizacije pomoću katetera YU23901A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10245798P 1998-09-30 1998-09-30

Publications (1)

Publication Number Publication Date
YU23901A true YU23901A (sh) 2003-07-07

Family

ID=22289955

Family Applications (1)

Application Number Title Priority Date Filing Date
YU23901A YU23901A (sh) 1998-09-30 1999-07-08 Upotreba sredstva za snižavanje holesterola u sprečavanju i odlaganju revaskularizacije pomoću katetera

Country Status (35)

Country Link
US (1) US20080119561A1 (sh)
EP (1) EP1117392B1 (sh)
JP (1) JP2002525321A (sh)
KR (1) KR20010079955A (sh)
CN (1) CN1197565C (sh)
AP (1) AP1708A (sh)
AT (1) ATE260100T1 (sh)
AU (1) AU768474B2 (sh)
BG (1) BG105471A (sh)
BR (1) BR9914098A (sh)
CA (1) CA2343299C (sh)
CZ (1) CZ20011035A3 (sh)
DE (1) DE69915084T2 (sh)
DK (1) DK1117392T3 (sh)
EA (1) EA007427B1 (sh)
EE (1) EE200100199A (sh)
ES (1) ES2214872T3 (sh)
HK (1) HK1042436A1 (sh)
HR (1) HRP20010236A2 (sh)
HU (1) HUP0103648A3 (sh)
ID (1) ID30255A (sh)
IL (2) IL141953A0 (sh)
IS (1) IS5889A (sh)
NO (1) NO20011615L (sh)
NZ (1) NZ510500A (sh)
OA (1) OA11787A (sh)
PL (1) PL346980A1 (sh)
PT (1) PT1117392E (sh)
SI (1) SI1117392T1 (sh)
SK (1) SK4122001A3 (sh)
TR (1) TR200100901T2 (sh)
UA (1) UA73292C2 (sh)
WO (1) WO2000018395A1 (sh)
YU (1) YU23901A (sh)
ZA (1) ZA200102230B (sh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078747A1 (de) * 2000-04-18 2001-10-25 Bayer Aktiengesellschaft Verwendung von cse-hemmern zur behandlung von herzinsuffizienz
CA2414783A1 (en) * 2000-07-14 2002-01-24 Warner-Lambert Company Treatment of eating disorders using carboxyalkylethers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5807388A (en) * 1994-05-25 1998-09-15 The Trustees Of Columbia University In The City Of New York Myocardial revascularization through the endocardial surface using a laser
WO1995013063A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
AU720853B2 (en) * 1995-11-02 2000-06-15 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration
SE506272C2 (sv) * 1996-03-18 1997-11-24 Paul Edholm Förfarande och anordning för att bestämma bildläge och bildvinkel i en röntgenbild
IL117702A0 (en) * 1996-03-28 1996-07-23 Tel Aviv Medical Center Resear Drug for hyperlipoproteinemia
WO1998001100A2 (en) * 1996-07-09 1998-01-15 Merck & Co., Inc. Method for treating homozygous familial hypercholesterolemia
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
CA2343299A1 (en) 2000-04-06
EP1117392A1 (en) 2001-07-25
OA11787A (en) 2005-07-26
EE200100199A (et) 2002-06-17
NO20011615L (no) 2001-04-24
DK1117392T3 (da) 2004-06-14
AU768474B2 (en) 2003-12-11
BR9914098A (pt) 2001-07-31
CA2343299C (en) 2008-04-01
ES2214872T3 (es) 2004-09-16
HUP0103648A3 (en) 2003-10-28
US20080119561A1 (en) 2008-05-22
HRP20010236A2 (en) 2002-04-30
UA73292C2 (en) 2005-07-15
PT1117392E (pt) 2004-07-30
IL141953A0 (en) 2002-03-10
ID30255A (id) 2001-11-15
HK1042436A1 (en) 2002-08-16
EP1117392B1 (en) 2004-02-25
SK4122001A3 (en) 2002-06-04
HUP0103648A2 (hu) 2003-08-28
SI1117392T1 (en) 2004-06-30
EA200100370A1 (ru) 2001-10-22
AU4975099A (en) 2000-04-17
DE69915084T2 (de) 2004-07-22
WO2000018395A1 (en) 2000-04-06
TR200100901T2 (tr) 2001-08-21
CZ20011035A3 (cs) 2001-10-17
AP2001002112A0 (en) 2001-06-30
NO20011615D0 (no) 2001-03-29
PL346980A1 (en) 2002-03-11
EA007427B1 (ru) 2006-10-27
DE69915084D1 (de) 2004-04-01
BG105471A (en) 2001-12-31
IL141953A (en) 2006-07-05
ZA200102230B (en) 2002-06-18
KR20010079955A (ko) 2001-08-22
CN1342072A (zh) 2002-03-27
JP2002525321A (ja) 2002-08-13
CN1197565C (zh) 2005-04-20
NZ510500A (en) 2003-10-31
IS5889A (is) 2001-03-14
AP1708A (en) 2007-01-10
ATE260100T1 (de) 2004-03-15

Similar Documents

Publication Publication Date Title
YU23102A (sh) Jedinjenja za lečenje ishemije
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
DK1066056T4 (da) Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernmangel, fremgangsmåde til fremstilling af jerndextranforbindelsen og anvendelse af denne forbindelse til fremstilling af et...
AU1843500A (en) Methods and compositions for prevention and treatment of arterial lesions with non-steroidal anti-inflammatory drugs
WO1999044608A8 (en) New use
GEP20094818B (en) 2-methyl-thieno-benzodiaze-pine formulation
WO2002072021A3 (en) Agents and methods for the prevention of initial onset and recurrence of existing cancers
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
YU23901A (sh) Upotreba sredstva za snižavanje holesterola u sprečavanju i odlaganju revaskularizacije pomoću katetera
AU3386199A (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
AU2002215187A1 (en) S-adenosylmethionine and derivatives thereof for the treatment and prevention ofalzheimer's disease
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2001296224A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
CA2426543A1 (en) Anti-angiogenic polypeptides
AU2899099A (en) Composition for treatment and prevention of coronary artery disease
AU2002363227A1 (en) Methods for the treatment and diagnosis of tumorigenic and angiogenic disorders using 32616
AU2002256967A1 (en) Treating or reducing the risk of cardiovascular disease
NO20022084D0 (no) Blod for graveutstyr o.l
WO2001070093A3 (en) Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers
AU2001280953A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU4118900A (en) Methods for the gene therapy of benign prostatic hyperplasia and medical agents therefore
AU2344200A (en) Non-invasive acoustic detection of coronary artery disease
AU2001279103A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2002237570A1 (en) Therapeutic and/or preventive agent for diabetic ischemic heart disease
EP1321146A3 (en) Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use